Tempus AI (TEM) Looks Attractive Based on Results - Not Just Hype

AI stocks have continued to outperform in early 2026, and Tempus AI (TEM) is emerging as one of the more compelling names in the space. The company blends diagnostics, data, and machine learning to power personalized medicine - and the investment case is clearly gaining traction.

Tempus AI has started 2026 on a positive footing. A well-timed spotlight at the J.P. Morgan Healthcare Conference helped elevate the company’s visibility, while strong preliminary Q4 results underscored its accelerating revenue base and enterprise traction. With its next earnings report expected in late February or early March, investors will be watching closely to see if Tempus can sustain its rapid growth trajectory in H1 2026.

With investor interest in the AI sector continuing to grow, many investors are asking the core question: what exactly does Tempus AI do - and why is its platform drawing so much attention?

In short, Tempus AI aims to make precision medicine more personalized, scalable, and actionable. Founded in 2015 by Eric Lefkofsky, the company has developed one of the most advanced AI-enabled platforms in healthcare - designed to transform raw clinical and molecular data into structured insights that support diagnosis, treatment decisions, and clinical trial matching.

To achieve its commercial goals, Tempus integrates genetic testing with real-world patient data to deliver more personalized treatment strategies. The company’s platform sequences both DNA and RNA from tumor samples, then combines that data with electronic health records and clinical outcomes. Advanced machine learning models analyze these inputs to detect patterns, assess risk levels, and recommend treatments tailored to each patient’s unique tumor biology - rather than relying on population-level averages.

This approach empowers oncologists to move beyond one-size-fits-all protocols and deliver precision therapies tailored to each patient. But Tempus’ value extends beyond the clinic. For pharmaceutical partners, the company offers access to a vast, real-world dataset drawn from diverse healthcare settings - far broader than the narrow confines of traditional clinical trials. This data helps drug developers design more targeted studies, accelerate development timelines, and identify new opportunities for therapeutic innovation.

Tempus’ competitive edge comes from its timing, scale, and access to proprietary real-world data. As diagnostic testing becomes more routine, hospitals are producing enormous volumes of information - from lab reports and medical imaging to physician notes. Tempus has already partnered with over half of U.S. oncologists, collecting more than 8 million imaging files and 4 million diagnostic samples. This data powers its AI models, giving the company a significant lead in training scale, clinical relevance, and platform maturity.

With solutions like Tempus NOW (for rapid genomic reporting), COHORTS (for custom data cohorts), and AI-driven pathology tools from its Ambry Genetics and Paige acquisitions, Tempus is positioned to lead the shift toward data-driven, biomarker-guided medicine. These offerings support faster diagnostics, more precise patient stratification, and deeper insights for both clinicians and pharmaceutical partners - reinforcing Tempus’ role at the intersection of precision care and scalable AI infrastructure.

Tempus AI’s rapid growth is backed by a strong revenue base, expanding margins, and rising investor confidence.

In 2025, the company generated approximately $1.27 billion in revenue, up 83% year-over-year, with more than $955 million coming from its diagnostics segment. That growth was powered by rising test volumes - oncology testing rose 26%, while hereditary testing increased 29% - as well as significant expansion in data licensing, which jumped 38% for the year. Revenue from the data segment reached roughly $316 million, up 31% year-over-year.

These results were already evident in Tempus’ Q3 earnings, released in early November 2025, which showed $334 million in revenue, up 85% from the prior year and above consensus estimates. While the company posted a net loss of $80 million, it delivered positive adjusted EBITDA of $1.5 million, a notable improvement from a $21.8 million EBITDA loss in the prior-year period. Moreover, gross profit nearly doubled to $210 million, with gross margins expanding by 400 basis points to 64%.

That momentum has carried into early 2026. Earlier this month, Tempus released preliminary Q4 results projecting total revenue of $367 million - a year-over-year increase of 83%. A significant driver of that growth was the diagnostics segment, which is expected to contribute $266 million, up 121% from the prior year. Meanwhile, revenue from the data and applications segment is projected at $100 million, with insights growth accelerating on an adjusted basis.

These results point to simultaneous strength across both sides of the business - highlighting how Tempus is scaling both its testing volume and its AI-powered data services.

In addition to its top-line growth, Tempus also reported a record Total Contract Value (TCV) of more than $1.1 billion for 2025 - reflecting both new demand and deepening client relationships. Over the course of the year, the company signed more than 70 new data agreements, including notable partnerships with AstraZeneca, Pfizer, Novartis, Bristol Myers Squibb, and GSK. Net Revenue Retention stands at approximately 126%, underscoring Tempus’ ability to expand wallet share with existing clients while continuing to grow its customer base.

With earnings expected in late February or early March (date still unconfirmed), Tempus AI enters the event with strong momentum. Analyst sentiment reflects that strength: 7 out of 15 firms currently rate the stock a “buy,” and the average price target sits at $90 - well above the current share price near $65. That upside gap points to growing conviction in Tempus’ long-term growth outlook and its improving ability to scale operations profitably.

While Tempus AI is not yet profitable on a GAAP basis, its valuation appears increasingly grounded in fundamentals rather than just future promise. The current Price-to-Sales (P/S) ratio of roughly 10 may seem elevated at first glance - but it looks reasonable when viewed through the lens of 80%+ top-line growth, rising gross margins, and improving EBITDA.

Importantly, Tempus is making measurable progress toward profitability. Gross margins are expanding, operational leverage is beginning to show, and both the diagnostics and data segments are scaling in tandem. That operational improvement helps explain the stock’s sharp rally - up nearly 40% over the past year - and suggests further upside could be in store if execution stays on track.

All told, Tempus AI has evolved from a high-potential story into a credible, operationally-focused growth platform. With improving financials, a record contract pipeline, and expanding relationships with leading healthcare and pharmaceutical players, the company looks increasingly well-positioned heading into Q4 earnings.